Elucidating the mechanism by which NTM resist and inactivate LL-37 will provide leverage in developing more unconventional approaches to therapeutics with novel mechanisms of action to slow the progression of this emerging lung disease; i. e., development of agents to counter the NTM component(s) that neutralize LL-37. This evidence concerns the gene CAMP and lung disorder.